Cargando…
A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy
BACKGROUND: Non-small cell lung cancer (NSCLC) causes most of cancer related deaths in humans and is characterized by poor prognosis regarding efficiency of chemotherapeutical treatment and long-term survival of the patients. The purpose of the present study was the development of a human ex vivo ti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1913052/ https://www.ncbi.nlm.nih.gov/pubmed/17567922 http://dx.doi.org/10.1186/1465-9921-8-43 |
_version_ | 1782134054378799104 |
---|---|
author | Lang, Dagmar S Droemann, Daniel Schultz, Holger Branscheid, Detlev Martin, Christian Ressmeyer, Anne R Zabel, Peter Vollmer, Ekkehard Goldmann, Torsten |
author_facet | Lang, Dagmar S Droemann, Daniel Schultz, Holger Branscheid, Detlev Martin, Christian Ressmeyer, Anne R Zabel, Peter Vollmer, Ekkehard Goldmann, Torsten |
author_sort | Lang, Dagmar S |
collection | PubMed |
description | BACKGROUND: Non-small cell lung cancer (NSCLC) causes most of cancer related deaths in humans and is characterized by poor prognosis regarding efficiency of chemotherapeutical treatment and long-term survival of the patients. The purpose of the present study was the development of a human ex vivo tissue culture model and the analysis of the effects of conventional chemotherapy, which then can serve as a tool to test new chemotherapeutical regimens in NSCLC. METHODS: In a short-term tissue culture model designated STST (Short-Term Stimulation of Tissues) in combination with the novel *HOPE-fixation and paraffin embedding method we examined the responsiveness of 41 human NSCLC tissue specimens to the individual cytotoxic drugs carboplatin, vinorelbine or gemcitabine. Viability was analyzed by LIFE/DEAD assay, TUNEL-staining and colorimetric MTT assay. Expression of Ki-67 protein and of BrdU (bromodeoxyuridine) uptake as markers for proliferation and of cleaved (activated) effector caspase-3 as indicator of late phase apoptosis were assessed by immunohistochemistry. Transcription of caspase-3 was analyzed by RT-PCR. Flow cytometry was utilized to determine caspase-3 in human cancer cell lines. RESULTS: Viability, proliferation and apoptosis of the tissues were moderately affected by cultivation. In human breast cancer, small-cell lung cancer (SCLC) and human cell lines (CPC-N, HEK) proliferative capacity was clearly reduced by all 3 chemotherapeutic agents in a very similar manner. Cleavage of caspase-3 was induced in the chemo-sensitive types of cancer (breast cancer, SCLC). Drug-induced effects in human NSCLC tissues were less evident than in the chemo-sensitive tumors with more pronounced effects in adenocarcinomas as compared to squamous cell carcinomas. CONCLUSION: Although there was high heterogeneity among the individual tumor tissue responses as expected, we clearly demonstrate specific multiple drug-induced effects simultaneously. Thus, STST provides a useful human model to study numerous aspects of mechanisms underlying tumor responsiveness towards improved anticancer treatment. The results presented here shall serve as a base for multiple functional tests of novel chemotherapeutic approaches to NSCLC in the future. *Hepes – Glutamic acid buffer mediated Organic solvent Protection Effect |
format | Text |
id | pubmed-1913052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-19130522007-07-07 A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy Lang, Dagmar S Droemann, Daniel Schultz, Holger Branscheid, Detlev Martin, Christian Ressmeyer, Anne R Zabel, Peter Vollmer, Ekkehard Goldmann, Torsten Respir Res Research BACKGROUND: Non-small cell lung cancer (NSCLC) causes most of cancer related deaths in humans and is characterized by poor prognosis regarding efficiency of chemotherapeutical treatment and long-term survival of the patients. The purpose of the present study was the development of a human ex vivo tissue culture model and the analysis of the effects of conventional chemotherapy, which then can serve as a tool to test new chemotherapeutical regimens in NSCLC. METHODS: In a short-term tissue culture model designated STST (Short-Term Stimulation of Tissues) in combination with the novel *HOPE-fixation and paraffin embedding method we examined the responsiveness of 41 human NSCLC tissue specimens to the individual cytotoxic drugs carboplatin, vinorelbine or gemcitabine. Viability was analyzed by LIFE/DEAD assay, TUNEL-staining and colorimetric MTT assay. Expression of Ki-67 protein and of BrdU (bromodeoxyuridine) uptake as markers for proliferation and of cleaved (activated) effector caspase-3 as indicator of late phase apoptosis were assessed by immunohistochemistry. Transcription of caspase-3 was analyzed by RT-PCR. Flow cytometry was utilized to determine caspase-3 in human cancer cell lines. RESULTS: Viability, proliferation and apoptosis of the tissues were moderately affected by cultivation. In human breast cancer, small-cell lung cancer (SCLC) and human cell lines (CPC-N, HEK) proliferative capacity was clearly reduced by all 3 chemotherapeutic agents in a very similar manner. Cleavage of caspase-3 was induced in the chemo-sensitive types of cancer (breast cancer, SCLC). Drug-induced effects in human NSCLC tissues were less evident than in the chemo-sensitive tumors with more pronounced effects in adenocarcinomas as compared to squamous cell carcinomas. CONCLUSION: Although there was high heterogeneity among the individual tumor tissue responses as expected, we clearly demonstrate specific multiple drug-induced effects simultaneously. Thus, STST provides a useful human model to study numerous aspects of mechanisms underlying tumor responsiveness towards improved anticancer treatment. The results presented here shall serve as a base for multiple functional tests of novel chemotherapeutic approaches to NSCLC in the future. *Hepes – Glutamic acid buffer mediated Organic solvent Protection Effect BioMed Central 2007 2007-06-14 /pmc/articles/PMC1913052/ /pubmed/17567922 http://dx.doi.org/10.1186/1465-9921-8-43 Text en Copyright © 2007 Lang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Lang, Dagmar S Droemann, Daniel Schultz, Holger Branscheid, Detlev Martin, Christian Ressmeyer, Anne R Zabel, Peter Vollmer, Ekkehard Goldmann, Torsten A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy |
title | A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy |
title_full | A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy |
title_fullStr | A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy |
title_full_unstemmed | A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy |
title_short | A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy |
title_sort | novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1913052/ https://www.ncbi.nlm.nih.gov/pubmed/17567922 http://dx.doi.org/10.1186/1465-9921-8-43 |
work_keys_str_mv | AT langdagmars anovelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT droemanndaniel anovelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT schultzholger anovelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT branscheiddetlev anovelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT martinchristian anovelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT ressmeyeranner anovelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT zabelpeter anovelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT vollmerekkehard anovelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT goldmanntorsten anovelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT langdagmars novelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT droemanndaniel novelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT schultzholger novelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT branscheiddetlev novelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT martinchristian novelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT ressmeyeranner novelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT zabelpeter novelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT vollmerekkehard novelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy AT goldmanntorsten novelhumanexvivomodelfortheanalysisofmoleculareventsduringlungcancerchemotherapy |